15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
19:45 , Sep 10, 2018 |  BC Extra  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
22:54 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

RNA BiTEs

BioNTech AG believes its RNA therapeutics platform can produce bispecific antibodies that circumvent the manufacturing and short plasma half-life problems of other technologies, and thinks its approach can accelerate the development timeline for bispecific T...
23:02 , Jun 27, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms; drug delivery

TECHNOLOGY: Nucleic acids; other A method for delivering bispecific T cell-engaging antibodies as engineered mRNAs could prolong the serum half-life of the antibodies to treat cancer. mRNA encoding bispecific antibodies targeting CD3 and a second tumor...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

IMAB362: Phase II data

Top-line data from the open-label, European Phase II FAST trial in 161 patients with CLND18.2-positive advanced or recurrent gastric or gastroesophageal junction cancer who have not received previous chemotherapy showed that a loading dose of...
01:02 , Jun 7, 2016 |  BC Extra  |  Clinical News

Latest data show survival benefit for Ganymed's IMAB362

Updated data presented at the American Society of Clinical Oncology (ASCO) meeting showed IMAB362 from Ganymed Pharmaceuticals AG (Mainz, Germany) plus chemotherapy led to longer overall survival (OS) and progression-free survival (PFS) than chemotherapy alone...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Claudin 18 (CLDN18)-Rho GTPase activating protein 26 (ARHGAP26) fusion gene as a risk marker for gastric cancer

BiomarkersARHGAP26Claudin 18CLDN18Rho GTPase activating protein 26 (ARHGAP26)...